A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1

Trial Profile

A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Givosiran (Primary)
  • Indications Acute intermittent porphyria
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2018 According to an Alnylam Pharmaceuticals media release, Interim results were presented at the European Association for the Study of the Liver (EASL) 53rd Annual International Liver Congress 2018
    • 14 Apr 2018 Interim results published in an Alnylam Pharmaceuticals Media Release
    • 28 Mar 2018 According to an Alnylam Pharmaceuticals media release, new results will be presented the European Association for the Study of the Liver (EASL) 53rd Annual International Liver Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top